Among the 50 stocks in the Nifty index, 42 were trading in the green, while 8 were in the red. Shares of Vodafone Idea, ...

The stocks ranked 251st and lower are classified as small caps by AMFI; although stocks below ₹10,000 Crore in market cap are ...

AM(IST)on Monday in an upbeat market. Gland Pharma Ltd.(up 3.51 per cent), Cipla Ltd.(up 1.69 per cent), Abbott India Ltd.(up ...

Q4 results: Aurobindo Pharma, Firstcry parent Brainbees Solutions, KEC International, Nazara Technologies, Akums Drugs and Pharmaceuticals, Awfis Space Solutions, Blue Dart Express, General Insurance ...

Glenmark Pharma: The drug maker reported consolidated revenue of ₹3,256 crore, up 6.3% year-on-year (YoY) from ₹3,063 crore in the same quarter last year. NTPC: The PSU has posted a 22.6% sequential ...

Glenmark Pharmaceuticals to launch Brukinsa (zanubrutinib) in India after DCGI approval, offering treatment for five B-cell blood cancers with fewer cardiac side effects and flexible dosing options.

Stocks to Watch: NTPC, Ashok Leyland, JSW Steel, Paras Defence, Glenmark Pharma and more Here’s a quick look at stocks likely to be in focus in today's trade. Pranati Deva.

For the year ended March 31, 2025, Glenmark’s consolidated revenue stood at 13,321 crore, up 12.8 per cent over last year. Adjusted profit after tax (PAT) for the year ended March 31, 2025 was ...

Glenmark's US revenue saw a decline of $10 million quarter-on-quarter, down to $82.4 million, marking a 41-quarter low. The company attributed this drop to competitive pressures and a lack of ...

Motilal Oswal is bullish on Glenmark Pharma recommended buy rating on the stock with a target price of Rs 1690 in its research report dated May 26, 2025.

On the operating front, Glenmark’s EBITDA climbed 11 percent year-on-year to Rs 561 crore in Q4FY25, up from Rs 504 crore a year earlier. This led to an expansion in EBITDA margin to 17.2 ...